-
Mashup Score: 6
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The primary analysis of the Ro-CHOP phase III randomized controlled trial (ClinicalTrials.gov identifier: NCT01796002) established that romidepsin (Ro) plus cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) did not yield an increased efficacy compared with CHOP alone as first-line treatment of peripheral T-cell lymphoma. We report the planned final analysis 5 years after the last patient enrolled. With a median follow-up of 6 years, median progression-free survival (PFS) was 12.0 months compared with 10.2 months (hazard ratio [HR], 0.79 [95% CI, 0.62 to 1.005
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 16LYSARC sur LinkedIn : #lysarc #recherche #lymphomefolliculaire #ia #innovation #santé #bidifly - 2 month(s) ago
🚀 Le LYSA/LYSARC, IFLI (Institute for Follicular Lymphoma Innovation) et l’institut Curie ont eu le plaisir de lancer de leur programme de recherche BIDIFLY…
Source: fr.linkedin.comCategories: General Medicine News, Onc News and JournalsTweet-
A look back at the launch of the BIDIFLY research programme in Paris on 26th March! 🔬 BIDIFLY (Biological and Imaging Data Integration for Follicular Lymphoma Research) or how artificial intelligence is revolutionising follicular lymphoma research. https://t.co/6FKIQtDVvT https://t.co/E06Q0WokQ3
-
-
Mashup Score: 7
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The primary analysis of the Ro-CHOP phase III randomized controlled trial (ClinicalTrials.gov identifier: NCT01796002) established that romidepsin (Ro) plus cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) did not yield an increased efficacy compared with CHOP alone as first-line treatment of peripheral T-cell lymphoma. We report the planned final analysis 5 years after the last patient enrolled. With a median follow-up of 6 years, median progression-free survival (PFS) was 12.0 months compared with 10.2 months (hazard ratio [HR], 0.79 [95% CI, 0.62 to 1.005
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet-
[Publication LYSA dans le @JCO_ASCO] « Avec un suivi de 6 ans, l’étude Ro-CHOP reste négative mais bénéfice potentiel de la romidepsine dans les PTCL-TFH et du BV+chimio en cas de rechute. » Publication de @VincentCamus76 & @BachyEmmanuel https://t.co/nXmDChZ5t3 https://t.co/k2VS0Jx5EY
-
-
Mashup Score: 0ASH 2023 - Lymphoma Research Experts - 5 month(s) ago
Tazemetostat in Combination with RCHOP in Patients with high-risk, frontline Follicular Lymphoma (Epi-RCHOP): a phase II study from the LYSA Results of the EpiRCHOP phase II study, evaluating the efficacy o f tazemetostat in combination with R-CHOP in elderly newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a LYSA Study R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomize
Source: lymphoma-research-experts.orgCategories: General Medicine News, Onc News and JournalsTweet-
[LYSA presentations in Congresses] 📢 @ASH_hematology congress willstart this dec 9th @LysaLymphoma will present 14 oral communications and 13 posters Details of the presentations here: https://t.co/qynUrPn6SC Stay Tuned ! https://t.co/XZ8k6BT6Ab
-
-
Mashup Score: 5ASH 2023 - Lymphoma Research Experts - 6 month(s) ago
Tazemetostat in Combination with RCHOP in Patients with high-risk, frontline Follicular Lymphoma (Epi-RCHOP): a phase II study from the LYSA Results of the EpiRCHOP phase II study, evaluating the efficacy o f tazemetostat in combination with R-CHOP in elderly newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a LYSA Study R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomize
Source: lymphoma-research-experts.orgCategories: General Medicine News, Onc News and JournalsTweet-
[LYSA presentations in Congresses] 📢 @ASH_hematology congress willstart this dec 9th @LysaLymphoma will present 14 oral communications and 13 posters Details of the presentations here: https://t.co/qynUrPn6SC Stay Tuned ! https://t.co/XZ8k6BT6Ab
-
-
Mashup Score: 3
Patients et proches, afin de vous aider à vous informer sur les lymphomes, le « Lymphosite » a été conçu pour vous. Fruit d’une collaboration entre ELLyE, association de patients et de proches, du LYSA, principal réseau français indépendant de recherche sur les lymphomes et du FILO principal réseau français indépendant de recherche sur les leucémies lymphoïdes chroniques, ce site regroupe des vidéos claires et concises, vous apportant un maximum d’informations sur de nombreux aspects : la maladie, son
Source: www.lymphosite.frCategories: General Medicine News, Onc News and JournalsTweet-
RT @AssoELLyE: Connaissez vous https://t.co/mUwhV7CT5d, notre plateforme d'ℹ️ 🤔? Grâce à ses vidéos claires et didactiques, vous saurez t…
-
-
Mashup Score: 6LYSARC sur LinkedIn : #bidifly #cancer #ia #lysa #ifli #innovation #lymphome #santé #lysarc #lysa - 6 month(s) ago
📢 Annonce d’un nouveau partenariat entre le LYSA-LYSARC et l’Institute for Follicular Lymphoma Innovation (IFLI) ! 🤝 🔬 Lancement de BIDIFLY : un programme…
Source: fr.linkedin.comCategories: General Medicine News, Onc News and JournalsTweet-
[Partnership LYSA-LYSARC & IFLI] 🔬 Launch of BIDIFLY: a collaborative research program that uses advanced new AI tools to improve understanding of follicular lymphoma biology and accelerate the development of innovative treatments. More : https://t.co/U6irUFq1xA @clementinesar
-
-
Mashup Score: 16High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma - 6 month(s) ago
Key Points. PMBL patients with high gene expression of both PDL1 and PDL2 identified by GEP assay represent a subset of 23-30% of the population.These patients
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet-
In newly diagnosed PMBL patients, high gene expression of both PDL1 and PDL2 genes identified by GEP assay represent a subset of 23-30% of the population with strong immune privilege and poorer outcomes from first-line immunochemotherapy By @VincentCamus76 https://t.co/8jDJAlHACQ https://t.co/U2kUVW3YcP
-
-
Mashup Score: 1
Patients et proches, afin de vous aider à vous informer sur les lymphomes, le « Lymphosite » a été conçu pour vous. Fruit d’une collaboration entre ELLyE, association de patients et de proches, du LYSA, principal réseau français indépendant de recherche sur les lymphomes et du FILO principal réseau français indépendant de recherche sur les leucémies lymphoïdes chroniques, ce site regroupe des vidéos claires et concises, vous apportant un maximum d’informations sur de nombreux aspects : la maladie, son
Source: www.lymphosite.frCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @AssoELLyE: Connaissez vous https://t.co/mUwhV7CT5d, notre plateforme d'ℹ️ 🤔? Grâce à ses vidéos claires et didactiques, vous saurez t…
-
-
Mashup Score: 5Non-Relapse Mortality after CAR T-Cell therapy for Large B-Cell Lymphoma: A LYSA Study from the DESCAR-T Registry - 9 month(s) ago
Key Points. The NRM rate estimate after CAR-T cells for LBCL is 5%, with about 80% of deaths occuring beyond day 28 post-infusionInfections are responsible for
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @LemoineJean6: https://t.co/KgKAP6yP4S Proud of our work on NRM after CAR-T conducted on the french registry DESCAR-T @BloodAdvances @…
-
[Publication LYSA dans le @JCO_ASCO] « Avec un suivi de 6 ans, l’étude Ro-CHOP reste négative mais bénéfice potentiel de la romidepsine dans les PTCL-TFH et du BV+chimio en cas de rechute. » Publication de @VincentCamus76 & @BachyEmmanuel https://t.co/nXmDChZ5t3 https://t.co/k2VS0Jx5EY